Resources Investment Advisors, Llc. Fate Therapeutics Inc Call Options Transaction History

Resources Investment Advisors, Llc.

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 08, 2022	SELL	$17.78 - $42.39 $1.76 Million - $4.2 Million	-99,000 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$67.25 - $92.52 $40,350 - $55,512	-600 Reduced 0.6%	99,000 $8.59 Million
Q1 2021 May 10, 2021	BUY	$72.16 - $117.4 $43,296 - $70,440	600 Added 0.61%	99,600 $8.21 Million
Q4 2020 Feb 08, 2021	SELL	$38.09 - $100.95 $60,944 - $161,520	-1,600 Reduced 1.59%	99,000 $9 Million
Q3 2020 Oct 09, 2020	SELL	$30.41 - $40.5 $124,681 - $166,050	-4,100 Reduced 3.92%	100,600 $4.02 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $64,672 - $112,735	-3,200 Reduced 2.97%	104,700 $3.59 Million
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $331,776 - $612,096	-19,200 Reduced 15.11%	107,900 $2.4 Million
Q4 2019 Feb 07, 2020	BUY	$13.39 - $20.73 $1.7 Million - $2.63 Million	126,700 Added 31675.0%	127,100 $2.49 Million
Q3 2019 Nov 08, 2019	SELL	$15.47 - $22.5 $41,769 - $60,750	-2,700 Reduced 87.1%	400 $6,000
Q2 2019 Aug 12, 2019	BUY	$15.61 - $20.44 $48,391 - $63,364	3,100 New	3,100 $0

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Resources Investment Advisors, Llc., based on Form 13F filings with the SEC.

Stay updated on Resources Investment Advisors, Llc. with notifications on news.